Review Article

International Urogynecology Journal

, Volume 23, Issue 8, pp 983-991

Solifenacin for overactive bladder: a systematic review and meta-analysis

  • Deyi LuoAffiliated withDepartment of Urology, West China Hospital, Sichuan University
  • , Liangren LiuAffiliated withDepartment of Urology, West China Hospital, Sichuan University
  • , Ping HanAffiliated withDepartment of Urology, West China Hospital, Sichuan University
  • , Qiang WeiAffiliated withDepartment of Urology, West China Hospital, Sichuan University
  • , Hong ShenAffiliated withDepartment of Urology, West China Hospital, Sichuan University Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

This study aims to evaluate the efficacy and safety of solifenacin for treating overactive bladder. Randomized controlled trials (RCTs) were identified and extracted from MEDLINE, Embase, and CENTRAL. The quality of the included RCTs was assessed using the Jadad score, and heterogeneity was analyzed using the chi-squared test. The data of the included RCTs were collected, extracted, and assessed by our protocol. A total of nine RCTs were identified from the search strategy. Compared with the placebo and tolterodine treatments, both short-term (mostly 12-week) trials indicated that solifenacin significantly reduced urgency episodes, micturitions, and incontinence episodes per 24 h. Compared with the solifenacin (5 mg) group, the solifenacin (10 mg) group was significantly better in terms of the number of micturitions per 24 h. With regard to adverse effects, the patients treated with solifenacin had significantly higher rates of constipation and blurred vision than patients treated with tolterodine. The solifenacin therapy was not inferior to tolterodine in terms of efficacy profiles and had a similar incidence of overall adverse events compared with tolterodine treatment. Solifenacin (5 mg) is thus a recommended dose because of its reported balance between efficacy and acceptable tolerability.

Keywords

Solifenacin Overactive bladder Tolterodine